O-1602
Chemical Name: 5-Methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol
Purity: ≥97%
Biological Activity
O-1602 is an analog of cannabidiol that is a potent agonist at the GPR55 cannabinoid receptor (EC50 values are 13, > 30000 and > 30000 nM for GPR55, CB1 and CB2 receptors respectively). Induces activation of RhoA, cdc42 and rac1. Increases proliferation of neural stem cells NSCs in vitro and in vivo. Also promotes neurogenesis in vivo.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis.
Hill et al.
Br.J.Pharmacol., 2018;175:3407 -
The orphan receptor GPR55 is a novel cannabinoid receptor.
Ryberg et al.
Br.J.Pharmacol., 2007;152:1092 -
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
Johns et al.
Br.J.Pharmacol., 2007;152:825
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for O-1602
The citations listed below are publications that use Tocris products. Selected citations for O-1602 include:
10 Citations: Showing 1 - 10
-
Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells.
Authors: Schwartz Et al.
Oncotarget 2018;9:34595
-
Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis.
Authors: Hill Et al.
Br.J.Pharmacol. 2018;175:3407
-
Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells.
Authors: Saliba Et al.
J Neuroinflammation 2018;15:322
-
The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress.
Authors: Shi
Mol Brain 2017;10(1):38
-
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.
Authors: Hanlon Et al.
Breast Cancer (Dove Med Press) 2016;8:59
-
Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
Authors: Ailte Et al.
Scientific Reports 2016;6:30336
-
△(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.
Authors: Williams Et al.
Immunol Cell Biol 2014;9:369
-
A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans.
Authors: Romero-Zerbo Et al.
J Endocrinol 2011;211:177
-
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.
Authors: Schicho Et al.
Inflamm Bowel Dis 2011;17:1651
-
Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries.
Authors: Daly Et al.
Br J Pharmacol 2010;159:787
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for O-1602
There are currently no reviews for this product. Be the first to review O-1602 and earn rewards!
Have you used O-1602?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
